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An alternative to the preoperative nomogram approach is the
use of techniques such as neurovascular structure-adjacent
frozen-section examination (NeuroSAFE) [6]. This allows an
intraoperative decision on the extent of excision, based on
frozen-section examination, and it has been shown to
increase the ability to nerve-spare, with associated improved
functional outcomes, whilst reducing positive surgical
margins. However, it does have significant cost implications
and is not widely available.
It makes sense to use preoperative MRI, currently widely
recommended for staging, in combination with clinical
parameters, to maximise the use of nerve-sparing to favour
functional outcomes, whilst minimising positive surgical
margins. Martini et al. [1] present a nomogram based on
readily available parameters, which could be readily adopted
in the routine setting. The move towards MRI before first
biopsy is likely to give us more accurate imaging data, which
should help us to further refine the decision to nerve-spare
for men undergoing radical prostatectomy.
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A novel nomogram for predicting ECE of prostate
cancer
We read with great interest the publication on the side-
specific multiparametric magnetic resonance imaging
(mpMRI)-based nomogram from Martini et al. [1].
The prediction of extracapsular extension (ECE) of prostate
cancer is of utmost importance to inform accurate surgical
planning before radical prostatectomy (RP).
Today, surgical strategy is tailored to the patient’s
characteristics, and the need for a correct prediction of
ECE is of paramount importance to guarantee oncological
safety, as well as optimal functional outcome. The most
up-to-date guidelines suggest referring to nomograms to
decide whether or not to perform nerve-sparing (NS)
surgery. Since the first version of the Partin Tables in
1993, several models have been developed based on PSA,
Gleason score at prostate biopsy, and clinical staging, as
the most used covariates.
Furthermore, mpMRI is increasingly used in the diagnostic
pathway of prostate cancer to aid prostate biopsy targeting
and to attain a more accurate diagnosis of clinically
significant prostate cancer. Despite its recognised role in the
detection of cancer, the accuracy for local staging is poor,
providing a low and heterogeneous sensitivity for the
detection of ECE [2].
Given this limitation, the addition of MRI to clinically-
derived nomograms might result in an improved assessment
of preoperative local staging. In a retrospective analysis of
501 patients who underwent RP, MRI + clinical models
outperformed clinical-based models alone for all staging
outcomes, with better discrimination in predicting ECE
with MRI + Partin Tables and MRI + Cancer of the
Prostate Risk Assessment (CAPRA) score than nomograms
alone [3].
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In the current article, Martini et al. [1] suggest a novel
nomogram for predicting ECE that includes the presence of a
‘documented definite ECE at mpMRI’ as an additional
variable beyond PSA, Gleason score, and maximum
percentage of tumour in the biopsy core with the highest
Gleason score. Readers should recognise that this is the first
model integrating side-specific MRI findings together with
side-specific biopsy data to provide a ‘MRI-based side-specific
prediction of ECE’, in an effort to support the surgical
decision for a uni- or bilateral NS approach.
However, given the frail generalisability of nomograms in
different datasets even after external validation [4], a
predictive tool has to be built on a rigorous methodology
with clear reproducibility of all steps the covariates derive
from.
In this respect, the current model raises some concerns.
The schedule of preoperative MRI assessment is arbitrary,
with imaging being performed either before (23.9%) or after
systematic biopsy (76.1%), and amongst patients with a MRI
prior to biopsy, only 94 of 134 patients underwent additional
targeted sampling. As a result, MRI is applied by chance in
three different ways: before prostate biopsy without targeted
sampling, before prostate biopsy with targeted sampling, and
after prostate biopsy.
Based upon this heterogeneous MRI timing, the performance
of such a model in a novel population may be biased
depending on the diagnostic pathway applied at each
institution.
The choice of the variables included represents another point
of concern. The output of two out of four covariates, ECE
depiction at mpMRI and the percentage of tumour in the
biopsy core, have been deliberately dichotomised, without
taking into account the continuous trend intrinsic to both
variables.
Actually, local staging in the European Society of Urogenital
Radiology (ESUR) guidelines has been scored on a 1–5 point
scale to grade the likelihood of an ECE event. The authors
deliberately dichotomised mpMRI findings, considering ‘the
loss of prostate capsule and its irregularity’ as suggestive of
ECE and ‘broad capsular contact, abutment or bulge without
gross ECE’ evocative of organ-confined disease. As a result,
the included MRI covariate may account for a gross
prediction of ECE, maintaining the inaccurate and inter-
reader subjective interpretation of local staging intrinsic to
MRI.
Beyond those methodological concerns and the moderate
sample size that may limit the reproducibility of the model,
we wonder if such a prediction really assists the surgeon’s
capability to perform a tailored surgery.
The ‘all or none’ era of NS surgery is over, and we are
currently able to grade NS according to different
approaches reported in the literature. Particularly, Tewari
et al. [5] proposed a NS approach based on four grades of
dissection, with the veins on the lateral aspect as vascular
landmarks to gain the correct dissection planes. Patel et al.
[6] described a five-grade scale of dissection, using the
arterial periprostatic vasculature as a landmark to the same
purpose.
If we are able to grade a NS surgery, the prediction of ECE
should be graded as well and should answer the prerequisite
of knowing the amount of prostate cancer extent outside the
capsule. How does a surgeon make the decision to follow a
more or less conservative dissection otherwise?
We tried to address this issue by using a tool aimed at
predicting the amount of ECE [the Predicting ExtraCapsular
Extension in Prostate cancer tool] [6] and supporting the
choice of the correct plane of dissection with a suggested
decision rule. In our study, developed on a large sample of
nearly 12 000 prostatic lobes and several combined
clinicopathological variables, the absence of imaging
characterization was the major point of weakness.
To date, the ideal predictive tool has yet to be described.
However, in the modern era of precision surgery, we think
that a model should encompass the surgical knowledge and
techniques currently available.
Future developments will probably include three-dimensional
surgical navigation models displayed on the TileProTM
function of the robotic console (Intuitive Surgical Inc.,
Sunnyvale, CA, USA), based on the integration of MRI (for
the number, size and location of disease) and predictive tools
(to define the amount of ECE).
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Urinary incontinence and the causality dilemma
Fundamentally, the aetiology of most female urinary
incontinence (UI) remains an enigma. Although we gain
comfort in our conceptualisations of anatomical defects and
neurological compromise as contributing factors, most of our
therapies for UI are directed at symptomatic control instead
of a disease prevention or modification. Thus, the principal
drivers of female UI symptoms remain elusive. The premise
of the series published in this issue by Markland et al. [1], to
identify patterns of comorbid conditions in patients with
various types of UI, is a valid and intriguing question, and
this effort provides an important component of emerging
concepts of the pathophysiology of UI development in
women. The authors describe the analysis of cross-sectional
data from the National Health and Nutrition Examination
Surveys (NHANES) and report on 3800 women with UI.
Exploration of associations between UI with patient
demographics and medical conditions revealed fascinating
relationships and not surprisingly, a high prevalence of
comorbid conditions in patients with self-reported UI. Thus,
despite the known limitations of such a cross-sectional
analysis, this study by Markland et al. [1] provides
provocative information to achieve actionable mandates.
The novel approach described in the article of developing
cluster analysis revealed four distinct patterns between UI and
multiple chronic conditions. One of the most dominant
relationships that merits intense exploration is the relationship
between common conditions of hypertension, hyperlipidaemia,
and increased cardiovascular disease (CVD) risk. Indeed, CVD
remains a leading cause of death in women in the USA [2].
Population-based analysis has hinted at possible connections
between CVD and UI, although determinative causality has not
been established [3,4]. UI in women may reflect a similar
vascular pathology to erectile dysfunction (ED) in men,
potentially resultant from a gradual compromise of the delicate
neurovascular anatomy required for normal sphincter and
detrusor activity. In women, no such prodromal syndrome or
symptom such as ED in men has been acknowledged to
prompt CVD screening in otherwise asymptomatic patients.
Alternately, one might interpret this cluster data to indicate
that multimorbid chronic conditions and increasing age are
sufficient in the development of UI, although assigning such
risk silos is disposed to misconceptions. The contribution of
polypharmacy in these clusters is a decidedly substantial
component for careful consideration. However, data extracted
from such survey sampling have inherent complexities that
limit defining causality, so how do we retrospectively discern
understanding viewing the insults of a lifetime resulting in
UI? The short answer is, we do not.
We must extract ourselves from the realm of symptom
suppression for women with UI and direct resources to a
broader view of the life course of the condition. In addition
to the expansive phenotyping efforts ongoing from the
National Institute of Diabetes and Digestive Kidney Disease
(NIDDK) through the Symptoms of Lower Urinary Tract
Dysfunction Research Network (LURN), no initiative speaks
to the endeavor to principally change paradigms about
bladder health in women more than the pioneering concept
of The Prevention of Lower Urinary Tract Symptoms (PLUS)
Research Consortium [5]. The PLUS consortium is dedicated
to promoting prevention of LUTS across the woman’s life
spectrum, which roots in the appreciation of progression of
factors contributing to disease. Without this critical
transdisciplinary approach, comprehension of the base
aetiology of UI, and our continued attempts to mask
symptoms, may propagate further deterioration of systemic
manifestations of primary high-risk diseases in our patients.
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